Journal of the Korean Pediatric Society 1986;29(10):1080-1086.
Published online October 31, 1986.
The relationship between Dose of Hepatitis B Vaccine and Seroconversion Rate in Infants.
Jung Hye Choi, Ki Sup Chung, Dong Gwan Han
Department of Pediatrics, Yonsei University College of Medicine
영아에 있어서 B형 간염백신의 용량과 면역 효과
최정혜, 정기섭, 한동관
연세대학교 의과대학 소아과학교실
After the discovery of Australia antigen by Blumberg et al in 1965, subsequent studies revealed that Australia antigen is identical with surface antigen of hepatitis B virus. The infants born to HBsAg positive mother can be protected from perinatal hepatitis B virus infection with hepatitis B vaccine and hepatitis B immunoglobulin. If the dose of vaccine can be reduced from usual child dose of 10μg to 5μg,the decrease in cost of mass immunization of infants will be possible. Two hundreds pregnant women who were admitted to Severance Hospital, Yonsei University College of Medicine for their deliveries, were 5 screened for serum hepatitisjB markers (HBs Ag, anti-HBc, anti-HBs, HBe Ag, anti-HBe) by radioimmunoassay. Of 200 pregnant women, 87 cases were negative for all hepatitis B markers. Among 87 infants born to all hepatitis B markers negative mothers, 46 infants had a perfect follow-up records, and 41 infants were missed during follow-up period. The babies were divided into two groups. In one group (n=21), 10 fig of Hepavax® (Green Cross Co., Korea) was administered intramuscularly at birth, 1 monts and 6 months of age, in another group (n=25), 5 of Hepavax® at birth and same intervals. And the anti-HBs was titrated by radioimmunoassay at 1 months, 3 monts, 6 months and 8 months of age. The results were as follows: 1) Of 200 pregnant women, 12 cases (6.0%) were positive for HBs Ag, 93 cases (46.5%) positive for anti-HBc, 84 cases (42.0%) positive for anti-HBs, and 6 cases (3.0%) positive for HBe Ag, but 87 cases (43.5%) were negative for all hepatitis B markers. 2) Seroconversion rate of 21 infants in 10μg-vaccinated group was 28.6% at 1 month after the first vaccination, 81.0% at 3 months, 81.0% at 6 months, and 90.5% at 8 months. Seroconversion rate of 25 infants in 5 μg-vaccinated group was 28.9%, 60.0%, 76.0%, and 88.0% respectively at the same intervals as 10 μg-vaccinated group. There were no significant differences in seroconversion rates between two groups. 3) Mean ratio unit values for anti-HBs determined in vaccine recipients, was slightly lower than that of 10 vaccine recipients, but there were no statistically significant differences between two groups. In conclusion, this result suggests that in infants the vaccination dose of 5μg for Hepa-vax® is sufficient to obtain comparable seroconversion rate to 10 fig vaccine recipients.
Key Words: Hepatitis B vaccine, Immune response.

Close layer
prev next